Linnaeus Therapeutics, Inc. Employee Directory
Biotechnology ResearchNew Jersey, United States2-10 Employees
Linnaeus Therapeutics is a small, privately held biotechnology company based in Haddonfield, New Jersey, focused on translating human biology into therapies for cancer, cardiometabolic diseases, and aging. Its work centers on activating GPER, a mechanism it links to tumor suppression, vascular health, metabolism, and brain function, with the aim of influencing aging trajectories. Founded in 2016 at the University of Pennsylvania by Christopher Natale and Todd Ridky, the company began with GPER-related discoveries and is pursuing oncology programs alongside aging biology research. Its lead program, LNS8801, is in oncology clinical trials, and the company is developing a broader pipeline in cardiometabolic disease and aging biology. Linnaeus Therapeutics has collaborated with Merck since 2020 to evaluate the combination of LNS8801 with pembrolizumab in selected advanced solid tumors. Recent coverage indicates the company is pursuing studies of a GPER-activating drug in melanoma patients whose cancer did not respond to immunotherapy.